Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Low to Int-2 Risk MDS
NCT00961064Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Mar 2011
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in myelodysplastic syndrome (MDS), sponsored by National Heart, Lung, and Blood Institute. Started Mar 2011; status: completed.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00961064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961064.